Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026)

Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 18.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 92.37%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Agios Pharmaceuticals 2.20 Bn 1.46 Bn 19.43 Mn -32.56%

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.56%
Dec 31, 2025 -11.93%
Sep 30, 2025 -110.91%
Jun 30, 2025 -19.43%
Mar 31, 2025 -15.24%
Dec 31, 2024 -0.61%
Sep 30, 2024 1,137.97%
Jun 30, 2024 -22.79%
Mar 31, 2024 -11.12%
Dec 31, 2021 130.17%
Sep 30, 2021 77.24%
Jun 30, 2021 61.85%
Mar 31, 2021 4,382.87%
Dec 31, 2020 87.70%
Sep 30, 2020 81.73%
Jun 30, 2020 92.06%
Mar 31, 2020 145.58%
Dec 31, 2019 77.90%
Sep 30, 2019 -11.98%
Jun 30, 2019 -58.93%